Volume | 80,208 |
|
|||||
News | - | ||||||
Day High | 1.25 | Low High |
|||||
Day Low | 1.18 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Personalis Inc | PSNL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.25 | 1.18 | 1.25 | 1.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
407 | 80,208 | $ 1.23 | $ 98,358 | - | 0.8906 - 2.60 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:32:56 | 2 | $ 1.23 | USD |
Personalis Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
65.66M | 50.50M | - | 73.48M | -108.3M | -2.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Personalis News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSNL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.22 | 1.4199 | 1.18 | 1.28 | 222,211 | 0.02 | 1.64% |
1 Month | 1.48 | 1.54 | 1.18 | 1.33 | 235,228 | -0.24 | -16.22% |
3 Months | 1.36 | 1.80 | 1.12 | 1.44 | 337,605 | -0.12 | -8.82% |
6 Months | 1.05 | 2.38 | 0.8906 | 1.47 | 511,229 | 0.19 | 18.10% |
1 Year | 2.31 | 2.60 | 0.8906 | 1.59 | 369,372 | -1.07 | -46.32% |
3 Years | 23.41 | 28.47 | 0.8906 | 7.68 | 443,490 | -22.17 | -94.70% |
5 Years | 23.70 | 53.46 | 0.8906 | 14.67 | 491,738 | -22.46 | -94.77% |
Personalis Description
Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. |